Were Nitazenes Present in Most Ontario Opioid Deaths? Read the 79-of-8,719 Denominator
Short answer: No. In coroner data analyzed for a Canadian study, nitazenes were present in 79 of 8,719 Ontario opioid deaths (0.91%) from January 2019 through December 2022. The Toronto subset was 33 of 1,803 opioid deaths (1.83%). These are presence counts in specified death records, not evidence that nitazenes caused every listed death or that the same fractions apply today.
Which denominator belongs to each figure?
Gelgoot and colleagues used Ontario coroner data for opioid deaths, with Toronto as a geographic subset. The numerator counts deaths in which a nitazene was present. The denominator counts opioid deaths in that jurisdiction and period. The study also analyzed drug-checking and police-seizure samples from January 2019 to July 2024. Those analytical submissions have a different selection process and a later endpoint; their percentages should not be mixed with the death fractions.
What does “present” establish?
It reports detection in the death data. It does not assign a sole cause of death, dose, timing or role relative to other substances for each person. The study describes co-occurring drugs in submitted material and uses separate data streams to examine broader market patterns. A specific death requires its autopsy, full toxicology, circumstances and medical findings.
Why not generalize the percentage?
The figures concern a defined period and jurisdiction. Testing panels, drug-market composition and case ascertainment can change. Ontario’s 0.91% and Toronto’s 1.83% are not national prevalence figures, and neither describes the proportion of all opioid users exposed to nitazenes. The correct statement keeps the place, time and opioid-death denominator attached.
The study shows that nitazenes appeared in some opioid-death investigations during that interval. It does not support a claim that they were present in most such deaths or establish their role in a particular case without its underlying records.
Scientific source
Gelgoot EA, Scarfone KM, Maghsoudi N, et al. The Detection of Novel Nitazene-Class Opioids in Unregulated Drug Markets in Canada. Drug and Alcohol Review. 2026;45:e70189. doi:10.1111/dar.70189. Based on the supplied full paper.



